At 8.6% CAGR, the South & Central America Breast Cancer Therapeutics Market Is Projected to be Worth US$ 2,953.26 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the South & Central America breast cancer therapeutics market was valued at US$ 1,530.71 million in 2022 and is expected to reach US$ 2,953.26 million by 2030, registering a CAGR of 8.6% from 2022 to 2030. Increased support from government and private organizations and growing burden of breast cancer are among the critical factors attributed to the South & Central America breast cancer therapeutics market expansion.

Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. In 2022, through the "Mulheres Amigas - Temporada Amazônia" program, Daiichi Sankyo Brasil (DSBR) started offering free breast cancer screenings to women in Brazil's Amazon region. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.

Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the South & Central America breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.

On the contrary, high cost of diagnosis and treatment hampers the growth South & Central America breast cancer therapeutics market.

Based on drug therapy, the South & Central America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 59.9% share of the South & Central America breast cancer therapeutics market in 2022, amassing US$ 917.24 million. It is projected to garner US$ 1,894.39 million by 2030 to expand at 9.5% CAGR during 2022–2030. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the South & Central America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 68.5% share of the South & Central America breast cancer therapeutics market in 2022, amassing US$ 1,049.27 million. It is projected to garner US$ 2,128.62 million by 2030 to expand at 9.2% CAGR during 2022–2030.

By distribution channel, the South & Central America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 73.6% share of South & Central America breast cancer therapeutics market in 2022, amassing US$ 1,126.35 million. It is projected to garner US$ 2,252.06 million by 2030 to expand at 9.0% CAGR during 2022–2030.

Based on country, the South & Central America breast cancer therapeutics market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil held 61.5% share of South & Central America breast cancer therapeutics market in 2022, amassing US$ 941.15 million. It is projected to garner US$ 1,914.39 million by 2030 to expand at 9.3% CAGR during 2022–2030.

Key players operating in the South & Central America breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.

• In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreement's terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.
• In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com